Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
AstraZeneca share price has gone vertical; brace for a pullback
04:59am, Thursday, 29'th Aug 2024
AstraZeneca (LON: AZN) share price is firing on all cylinders as it sits on its all-time high. It has soared in the last five consecutive weeks, the longest streak since April 2023.
QIAGEN expands QIAstat-Dx into precision medicine through partnership for companion diagnostics in chronic diseases
04:05pm, Wednesday, 28'th Aug 2024
New agreement expands collaboration with AstraZeneca beyond oncology, including complex chronic diseases // QIAGEN's syndromic testing platform QIAstat-Dx enables specialty care providers to make fast
AstraZeneca (AZN) Denies Rumors About UK Facility Relocation
12:20pm, Monday, 26'th Aug 2024
Per third-party reports, AstraZeneca (AZN) has refuted rumors about considering a change in the relocation of a vaccine manufacturing plant from the U.K. to the United States.
Rumours of AstraZeneca relocating vaccine ops to US ‘untrue'
05:08am, Friday, 23'rd Aug 2024
British biotech giant AstraZeneca PLC (LSE:AZN) has rebuffed claims that it is moving its vaccine operations to the US. A Financial Times report suggested that AstraZeneca could relocate its vaccine m
AstraZeneca warns of moving UK vaccine production to US, FT reports
04:11pm, Thursday, 22'nd Aug 2024
AstraZeneca has warned it could relocate its vaccine manufacturing site from the UK to the U.S. amid a deadlock in negotiations with the Labour government over plans to cut state aid promised to the p
Top 10 pharmaceutical companies in 2024: S&P Global's latest ratings and rankings
01:57pm, Monday, 19'th Aug 2024
In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comp
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Certain Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer.
FDA Expands AstraZeneca's (AZN) Imfinzi Label in Lung Cancer
12:16pm, Friday, 16'th Aug 2024
This approval is based on late-stage study data, which shows that treatment with AstraZeneca's (AZN) Imfinzi reduced the risk of recurrence by 32% in certain non-small cell lung cancer patients.
AstraZeneca receives another US approval for cancer drug Imfinzi
04:09am, Friday, 16'th Aug 2024
AstraZeneca PLC's (LSE:AZN) blockbuster immunotherapy cancer drug Imfinzi (durvalumab) has received another approval in the US. In combination with chemotherapy, patients suffering resectable early-
US FDA approves AstraZeneca's Imfinzi for lung cancer treatment
05:31pm, Thursday, 15'th Aug 2024
The U.S. Food and Drug Administration approved AstraZeneca's blockbuster cancer drug, Imfinzi, for the treatment of patients with a type of non-small cell lung cancer on Thursday.
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
09:06am, Thursday, 15'th Aug 2024
Diabetes treatments from Merck, Novo Nordisk and AstraZeneca will face the steepest cuts under the IRA, a list showed Thursday.
AstraZeneca (AZN) Imfinzi Combo Gets EU Nod for Uterine Cancer
07:26am, Thursday, 15'th Aug 2024
AstraZeneca's (AZN) Imfinzi plus Lynparza for treating certain patients with primary advanced or recurrent endometrial cancer is approved in the EU based on data from the phase III DUO-E study.
AstraZeneca's Imfinzi gets FDA priority review for type of lung cancer
02:11am, Thursday, 15'th Aug 2024
AstraZeneca said on Thursday the U.S. Food and Drug Administration (FDA) has granted its cancer drug Imfinzi a priority review for patients with limited-stage small cell lung cancer in the United Stat
Defying the Market: 3 Mega-Cap Stocks Soaring to New Highs
10:33am, Wednesday, 14'th Aug 2024
In a market characterized by uncertainty and volatility, it's increasingly rare to find stocks that are weathering the storm and thriving. Yet, a select few from various sectors are doing just that—
AstraZeneca faces state funding blow at Merseyside project
06:33am, Wednesday, 14'th Aug 2024
AstraZeneca PLC (LSE:AZN) will have to scale back plans to expand its Merseyside vaccine manufacturing site after it was revealed the government is set to cut some of the project's funding. Of the £4
